Wild-type IDH1 inhibition enhances chemotherapy response in melanoma

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-9966

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Wild-type IDH1 inhibition enhances chemotherapy response in melanoma ; volume:41 ; number:1 ; day:24 ; month:9 ; year:2022 ; pages:1-18 ; date:12.2022
Journal of experimental & clinical cancer research ; 41, Heft 1 (24.9.2022), 1-18, 12.2022

Creator: Zarei, Mehrdad
Hajihassani, Omid
Hue, Jonathan J.
Graor, Hallie J.
Loftus, Alexander W.
Rathore, Moeez
Vaziri-Gohar, Ali
Asara, John M.
Winter, Jordan M.
Rothermel, Luke D.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13046-022-02489-w

URN: urn:nbn:de:101:1-2022121221121561549717

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:25 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Zarei, Mehrdad
Hajihassani, Omid
Hue, Jonathan J.
Graor, Hallie J.
Loftus, Alexander W.
Rathore, Moeez
Vaziri-Gohar, Ali
Asara, John M.
Winter, Jordan M.
Rothermel, Luke D.
SpringerLink (Online service)

Other Objects (12)

Wild-type and mutated IDH1/2 enzymes and therapy responses

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Hochschulschrift

Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas

Wild-type and mutated IDH1/2 enzymes and therapy responses

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Hochschulschrift

Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas

Wild-type and mutated IDH1/2 enzymes and therapy responses

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Hochschulschrift

Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Wild-type IDH1 inhibition enhances chemotherapy response in melanoma

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Wild-type and mutated IDH1/2 enzymes and therapy responses

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas

Wild-type and mutated IDH1/2 enzymes and therapy responses

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas

Wild-type and mutated IDH1/2 enzymes and therapy responses

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Surgery for IDH1/2 wild-type glioma invading the corpus callosum

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia

Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas

Related objects

Reset password